lifestyle.ebusinessplanet.com

Author: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

April 30, 2026
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

March 31, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

March 10, 2026
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

March 8, 2026
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

February 3, 2026
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

January 27, 2026